Systematic Reviews and Meta- and Pooled Analyses Pelvic In fl ammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies
暂无分享,去创建一个
L. Kiemeney | A. Berchuck | A. Ziogas | H. Anton-Culver | M. Goodman | A. Wu | R. Ness | S. Olson | H. Risch | S. Narod | J. Doherty | J. Schildkraut | K. Moysich | F. Modugno | S. Jordan | E. Bandera | C. Pearce | M. Rossing | C. Phelan | P. Webb | A. Jensen | R. Edwards | E. Høgdall | V. Albieri | K. Wicklund | S. K. Kjaer | L. Massuger | Christina B. Rasmussen | R. Edwards | A. Wu
[1] A. Jemal,et al. Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.
[2] J. McAlpine,et al. Pelvic Inflammation and the Pathogenesis of Ovarian Cancer: A Cohort Study , 2014, International Journal of Gynecologic Cancer.
[3] Yurii B. Shvetsov,et al. Genital Powder Use and Risk of Ovarian Cancer: A Pooled Analysis of 8,525 Cases and 9,859 Controls , 2013, Cancer Prevention Research.
[4] A. Chandra,et al. Correlates of Self-Reported Pelvic Inflammatory Disease Treatment in Sexually Experienced Reproductive-Aged Women in the United States, 1995 and 2006–2010 , 2013, Sexually transmitted diseases.
[5] S. Kjaer,et al. Pelvic inflammatory disease and risk of invasive ovarian cancer and ovarian borderline tumors , 2013, Cancer Causes & Control.
[6] S. Schüler,et al. Ovarian epithelial tumors and reproductive factors: a systematic review , 2013, Archives of Gynecology and Obstetrics.
[7] Russell Vang,et al. Fallopian tube precursors of ovarian low‐ and high‐grade serous neoplasms , 2013, Histopathology.
[8] Sun exposure and risk of epithelial ovarian cancer , 2012, Cancer Causes & Control.
[9] S. Tworoger,et al. Tubal ligation, hysterectomy and ovarian cancer: A meta-analysis , 2012, Journal of Ovarian Research.
[10] M. Pike,et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies , 2012, The Lancet. Oncology.
[11] L. Kiemeney,et al. Adequacy of family history taking in ovarian cancer patients: a population-based study , 2012, Familial Cancer.
[12] C. Bunker,et al. Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drugs, or Acetaminophen and Risk of Ovarian Cancer , 2012, Epidemiology.
[13] S. Olson,et al. Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study , 2011, BMC women's health.
[14] W. Su,et al. Risk of ovarian cancer in women with pelvic inflammatory disease: a population-based study. , 2011, The Lancet. Oncology.
[15] I. Shih,et al. Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer--shifting the paradigm. , 2011, Human pathology.
[16] Barry Rosen,et al. Frequencies of BRCA1 and BRCA2 mutations among 1,342 unselected patients with invasive ovarian cancer. , 2011, Gynecologic oncology.
[17] Jeffrey R. Marks,et al. Association between DNA Damage Response and Repair Genes and Risk of Invasive Serous Ovarian Cancer , 2010, PloS one.
[18] B. Rosner,et al. Risk factors for epithelial ovarian cancer by histologic subtype. , 2010, American journal of epidemiology.
[19] Jinsong Liu,et al. Inflammation: A hidden path to breaking the spell of ovarian cancer , 2009, Cell cycle.
[20] M. Pike,et al. Markers of inflammation and risk of ovarian cancer in Los Angeles County , 2009, International journal of cancer.
[21] A. Parwani. Tumor cell type can be reproducibly diagnosed and is of independent prognostic significance in patients with maximally debulked ovarian carcinoma , 2009 .
[22] M. Goodman,et al. Association of two common single-nucleotide polymorphisms in the CYP19A1 locus and ovarian cancer risk. , 2008, Endocrine-related cancer.
[23] A. Whittemore,et al. Consortium analysis of 7 candidate SNPs for ovarian cancer , 2008, International journal of cancer.
[24] A. Green,et al. Talcum powder, chronic pelvic inflammation and NSAIDs in relation to risk of epithelial ovarian cancer , 2008, International journal of cancer.
[25] C. Harris,et al. Inflammation and cancer: An ancient link with novel potentials , 2007, International journal of cancer.
[26] L. Kiemeney,et al. Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. , 2007, Kidney international.
[27] H. Risch,et al. PGR +331 A/G and Increased Risk of Epithelial Ovarian Cancer , 2006, Cancer Epidemiology Biomarkers & Prevention.
[28] M. S. St. Louis,et al. Trends in Pelvic Inflammatory Disease Hospital Discharges and Ambulatory Visits, United States, 1985–2001 , 2005, Sexually transmitted diseases.
[29] L. Westrom. Decrease in incidence of women treated in hospital for acute salpingitis in Sweden , 2005 .
[30] J. Ross. Pelvic inflammatory disease. , 2005, Clinical evidence.
[31] B. Thomsen,et al. Hormone therapy and the impact of estrogen intake on the risk of ovarian cancer. , 2004, Archives of internal medicine.
[32] M. Pike,et al. Hormonal factors and the risk of invasive ovarian cancer: a population-based case-control study. , 2004, Fertility and sterility.
[33] Michal Abrahamowicz,et al. Modeling smoking history: a comparison of different approaches. , 2002, American journal of epidemiology.
[34] E Demidenko,et al. Two‐stage methods for the analysis of pooled data , 2001, Statistics in medicine.
[35] M. Morgan,et al. Factors related to inflammation of the ovarian epithelium and risk of ovarian cancer. , 2000, Epidemiology.
[36] D. Seminara,et al. Cancer risk estimates for family members of a population-based family registry for breast and ovarian cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[37] R. Ness,et al. Possible role of ovarian epithelial inflammation in ovarian cancer. , 1999, Journal of the National Cancer Institute.
[38] A. Jemal,et al. Global cancer statistics , 2011, CA: a cancer journal for clinicians.
[39] C. la Vecchia,et al. Pelvic inflammatory disease and risk of ovarian cancer. , 1996, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[40] H. Risch,et al. Pelvic inflammatory disease and the risk of epithelial ovarian cancer. , 1995, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.
[41] H. Risch,et al. Dietary fat intake and risk of epithelial ovarian cancer. , 1994, Journal of the National Cancer Institute.
[42] X. Shu,et al. Population-based case-control study of ovarian cancer in Shanghai. , 1989, Cancer research.
[43] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[44] W. Cates,et al. Self-reported pelvic inflammatory disease in the US: a common occurrence. , 1985, American journal of public health.
[45] D. Cramer,et al. Determinants of ovarian cancer risk. II. Inferences regarding pathogenesis. , 1983, Journal of the National Cancer Institute.
[46] M F Fathalla,et al. Incessant ovulation--a factor in ovarian neoplasia? , 1971, Lancet.
[47] Fathalla Mf. Incessant ovulation--a factor in ovarian neoplasia? [letter] , 1971 .
[48] F. Massey. The Kolmogorov-Smirnov Test for Goodness of Fit , 1951 .